Phase 1 × Leukemia, Lymphocytic, Chronic, B-Cell × Rituximab × Clear all
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT00392691 2019-05-15

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Swiss Cancer Institute

Phase 1 Completed
20 enrolled
NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Terminated
1 enrolled
NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
NCT01045928 2015-11-26

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
5 enrolled
NCT00176475 2013-09-17

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Rutgers, The State University of New Jersey

Phase 1 Terminated
2 enrolled